[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paroxysmal-atrial-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paroxysmal-atrial-fibrillation":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,44,66,86,110,131,155,179,209,228,252,272,291,319,340,368,393,420,441,465,485],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100627106","evaluation-of-novel-waveforms-delivered-using-the-farapulse-pfa-system-100627106",false,"NCT07444320","Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System","A Multicenter Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System in Patients With Atrial Fibrillation","IMPULSE-EVO","Inclusion Criteria:\n\n1. ≥ 18 years of age, or older if required by local law\n2. Persistent Atrial Fibrillation or Paroxysmal Atrial Fibrillation\n\n   1. Persistent AF Documented:\n\n      * Physician's note confirming the presence of persistent atrial fibrillation and the arrhythmia symptoms\n      * Within 180 days prior to Enrollment: A 24-hour continuous ECG recording confirming continuous AF OR Two (2) ECGs from any regulatory-cleared rhythm monitoring device showing continuous AF taken at least 7 days apart.\n\n      OR\n   2. Paroxysmal AF Documented:\n\n      * Physician's note confirming the presence of paroxysmal atrial fibrillation and the arrhythmia symptoms\n      * Within 180 days of the Enrollment Date, one (1) ECG from any regulatory-cleared rhythm monitoring device showing atrial Fibrillation (AF)\n3. Willing and capable of providing informed consent\n4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center\n\nExclusion Criteria:\n\n1. Atrial exclusions - any of the following atrial conditions:\n\n   1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter is not available, LA non-indexed volume \\> 100 mL. If both values are available, only the LA diameter will be used to confirm eligibility.\n   2. Any prior atrial endocardial, epicardial, or surgical ablation procedure for arrhythmia other than ablation for right-sided SVT or cavotricuspid isthmus ablation\n   3. Any prior atrial surgery\n   4. Current atrial myxoma\n   5. Current Left Atrial Thrombus\n   6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible)\n2. Cardiovascular Conditions - Any of the following cardiovascular conditions:\n\n   1. History of sustained ventricular tachycardia (VT) or any ventricular fibrillation (VF)\n   2. Atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible\u002Fnon-cardiac causes\n   3. Cardiac Devices and Implants:\n\n      * Current or anticipated pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy devices.\n      * Interatrial baffle, patent foramen ovale, or atrial septal defect closure device or patch.\n      * Any Left Atrial Appendage Closure or Occlusion Device, except a WATCHMAN™ device implanted \\> 90 days before Enrollment\n   4. Valvular Disease - Presence of any of the following:\n\n      * Any prosthetic heart valve, ring or repair\n      * Moderate to severe mitral valve stenosis\n      * More than moderate mitral regurgitation (≥ 3+)\n      * Moderate to severe aortic stenosis\n   5. Cardiomyopathy - Hypertrophic cardiomyopathy\n   6. Access Issues - Any IVC filter, known inability to obtain vascular access, or other contraindication to femoral access\n   7. Anticipated Cardiac Surgery - Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months\n3. Congenital Conditions - Any of the following congenital conditions:\n\n   a. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality\n4. Baseline Conditions - Any of the following conditions at Baseline:\n\n   1. Heart failure - Heart failure associated with NYHA Class III or IV\n   2. Ejection Fraction - Most recent documented LVEF \\\u003C 40% within the previous 12 months\n   3. Obesity: Body Mass Index (BMI) \\> 45.0 kg\u002Fm\\^2\n   4. Hematologic Condition: Known coagulopathy or bleeding disorder\n   5. Anticoagulation Contraindication: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation\n   6. Pregnancy - Women who are confirmed to be pregnant or lactating at the time of the ablation procedure\n   7. Pulmonary Disease - Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen\n   8. Malignancy - Active malignancy (other than non-melanoma skin cancers)\n   9. Gastrointestinal - Clinically significant gastrointestinal problems involving the esophagus or stomach, including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration\n   10. Infection - Known active systemic infection\n   11. Sleep Apnea - Untreated diagnosed obstructive sleep apnea with apnea-hypopnea index classification of severe (\\> 30 events per hour) as per the guidelines\n   12. Life Expectancy - Predicted life expectancy of less than one (1) year per investigator medical judgment\n   13. Concurrent Enrollment - Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility\n5. Any of the following events within 90 days of the Consent Date:\n\n   1. Coronary disease - Myocardial infarction (MI), unstable angina or coronary intervention\n   2. Pericardium - Pericarditis or symptomatic pericardial effusion\n   3. GI Bleeding - Gastrointestinal bleeding\n   4. Cardiac Surgery - Any cardiac surgery\n   5. Neurovascular Event - Stroke, TIA, or intracranial bleeding\n   6. Thromboembolism - Any active non-neurologic thrombus and\u002For thromboembolic event\n   7. Carotid Intervention - Carotid stenting or endarterectomy\n   8. Diabetes - Uncontrolled diabetes mellitus or a recorded HgbA1c \\> 8.0%\n6. Medical History - Any of the following conditions in the Medical History\n\n   1. Transplantation - Solid organ or hematologic transplant, or currently being evaluated for a transplant\n   2. Diaphragmatic Abnormality - Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis\n   3. Coronary Disease - Any documented history of Prinzmetal angina or severe non-revascularizable coronary disease\n   4. Renal Disease - Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \\\u003C 30 mL\u002Fmin\u002F1.73 m2, or with any history of renal dialysis or renal transplant\n   5. General Medical Conditions - Any other general health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multicenter, prospective, single-arm, feasibility study to evaluate the safety and effectiveness of the waveforms being delivered using the FARAPULSE PFA System in patients with Paroxysmal Atrial Fibrillation (PAF) and Persistent Atrial Fibrillation (PersAF).",[27,28],"Paroxysmal Atrial Fibrillation","Persistent Atrial Fibrillation",[30],"Pulsed Field Ablation","RECRUITING","2026-06-26",{"date":34,"type":35},"2026-06-30","ACTUAL",{"date":37,"type":35},"2026-02-12",{"date":39,"type":21},"2028-02",{"name":41,"class":42},"Boston Scientific Corporation","INDUSTRY",4,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100584886","catheter-ablation-using-a-novel-navigation-and-imaging-system-100584886","NCT06895187","Catheter Ablation Using a Novel Navigation and Imaging System","ENVIsIoN","Inclusion Criteria:\n\n* Subject is 18 years of age at the time of consent, or of legal age to give informed consent specific to state and national law\n* Subjects is eligible for a catheter ablation procedure with the VERAFEYE System as navigation and imaging system in the treatment of PAF (according to VERAFEYE System IFUs, current international and local guidelines and per physician discretion)\n* Subject is able to understand and willing to provide written informed consent\n* Subject is able to and willing to complete all study assessments associated with this clinical study at an approved clinical investigational center\n\nExclusion Criteria:",{"count":52,"type":21},100,"OBSERVATIONAL","The objective of the ENVIsIoN study is to collect data on the use of the VERAFEYE navigation and imaging system in patients indicated to undergo a catheter ablation procedure for the treatment of Paroxysmal Atrial Fibrillation (PAF).",[27],"NOT_YET_RECRUITING","2026-06-09",{"date":59,"type":35},"2026-06-10",{"date":61,"type":21},"2026-10-01",{"date":63,"type":21},"2027-10-01",{"name":65,"class":42},"LUMA Vision Ltd.",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100456704","stop-af-first-post-approval-study-100456704","NCT05227053","STOP AF First Post-Approval Study","STOP AF First Post-Approval Study, an Addendum to the Cryo Global Registry","Inclusion Criteria:\n\n* Subject has been diagnosed with symptomatic paroxysmal AF\n* Subject is ≥ 18 years of age or minimum age as required by local regulations\n* Planned pulmonary vein isolation (PVI) procedure using the commercially available Arctic Front™ cardiac cryoablation catheter System.\n* Willing to comply with study requirements and give informed consent (defined as legally effective, documented confirmation of a subject's voluntary agreement to participate in this clinical study) or authorization per institution and geographical requirements\n\nExclusion Criteria:\n\nHistory of AF treatment with a class I or III antiarrhythmic drug, including sotalol, with the intention to prevent an AF recurrence1\n\n. Subjects under the following conditions may be included in the study:\n\n1. Temporary treatment with a class I or III AAD (treatment at a therapeutic dose for a period of \\\u003C4 weeks prior to the index PVI procedure)\n2. Recent treatment with a class I or III AAD (within 6 months of the index PVI procedure) at a dose below therapeutic threshold according to the AHA\u002FACC\u002FHRS Guideline for the Management of Patients with Atrial Fibrillation\n3. A subject who has received a chemical cardioversion may be included in the study. This includes a chemical cardioversion prior to enrollment and between enrollment and ablation.\n\n   * Subject has had a prior atrial ablation (except for cavo-tricuspid isthmus (CTI) ablation for AFL)\n   * Subject is enrolled in a concurrent study that has not been approved for concurrent enrollment by the global study manager\n   * Subject with exclusion criteria required by local law",{"count":20,"type":21},"The STOP AF First PAS is a prospective, global, multi-center, observational trial.",[27],"2026-05-19",{"date":78,"type":35},"2026-05-22",{"date":80,"type":35},"2022-04-28",{"date":82,"type":21},"2028-04",{"name":84,"class":42},"Medtronic Cardiac Ablation Solutions",13,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":109},"100515796","pulmonary-vein-isolation-strategy-of-very-high-power-short-duration-in-patients-with-paroxysmal-atrial-fibrillation-100515796","NCT05996159","Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation","Pulmonary Vein Isolation Strategy of Very High Power Short Duration in Patients With Paroxysmal Atrial Fibrillation: Q-INDEX Trial","Inclusion Criteria:\n\n* Patients undergoing PVI for PAF\n\nExclusion Criteria:\n\n* Aged less than 19 years\n* Patients with persistent AF\n* Patients with previous ablation or surgery for AF\n* Patients with intracardiac thrombus or thromboembolic events within the previous 90 days\n* Patients with cardiac surgery or acute coronary syndrome within the previous 90 days\n* Patients with contraindication(s) for using oral anticoagulants\n* Patients with LA anteroposterior diameter of more than 55 mm\n* Patients with left ventricular ejection fraction less than 35%\n* Pregnants or those who plan to become pregnant during the study\n* Life expectancy less than a year","19 Years",{"count":95,"type":21},150,[24],"This study aims to investigate the effect of reducing ablation time for a hybrid approach of vHPSD and AI-guided ablation using the QDOT Micro catheter in PVI among patients with PAF.",[27],"2026-05-18",{"date":101,"type":35},"2026-05-20",{"date":103,"type":35},"2023-11-07",{"date":105,"type":21},"2027-05-01",{"name":107,"class":108},"Seoul National University Hospital","OTHER",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":109},"100403168","added-value-of-vein-of-marshal-ethanol-infusion-compared-to-superior-vena-cava-isolation-alone-in-patients-undergoing-repeat-ablation-for-recurrent-paroxysmal-atrial-fibrillation-despite-durable-pv-isolation-100403168","NCT04529785","Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation","Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable Pulmonary Vein Isolation","VEIN-AF","Inclusion Criteria:\n\n* Patients older than 18 years\n* Patients scheduled for a repeat ablation of PAF after a previous PVI\n* Confirmation of lasting pulmonary vein isolation at the time of randomization\n\nExclusion Criteria:\n\n* Patients with persistent atrial fibrillation\n* Previous ablation with isolation of the SVC, roofline, mitral line or previous vein of Marshal ethanol infusion\n* Left atrial thrombus. Left atrial appendage thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.\n* Left ventricular ejection fraction \\\u003C35%.\n* Cardiac surgery within the previous 90 days.\n* Expecting cardiac transplantation or other cardiac surgery within 180 days.\n* Coronary percutaneous transluminal coronary angioplasty\u002Fstenting within the previous 90 days or myocardial infarction within the previous 60 days.\n* Documented history of a thromboembolic event within the previous 90 days.\n* Diagnosed atrial myxoma.\n* Significant restrictive, constrictive, or chronic obstructive pulmonary disease with chronic symptoms.\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment\n* Women who are pregnant or who plan to become pregnant during the study.\n* Acute illness or active infection at time of index procedure\n* Advanced renal insufficiency\n* Unstable angina.\n* History of blood clotting or bleeding abnormalities.\n* Contraindication to anticoagulation.\n* Life expectancy less than 1 year.\n* Presence of a condition that precludes vascular access.\n* International Normalized Ratio greater than 3.5 within 24 hours of procedure - for patients taking warfarin.\n* Patient cannot be removed from antiarrhythmic drugs for reasons other than AF.\n* Unwilling or unable to provide informed consent.",{"count":52,"type":21},[24],"The superior vena cava (SVC) is one of the most common non pulmonary vein (PV)-triggers for atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency (RF)-ablation under close monitoring of the phrenic nerve. However, adding substrate modification and vein of Marshal (VoM) ethanol infusion to the ablation procedure might substantially improve long-term outcomes.\n\nThe aim of this study is to evaluate the recurrence rate 1 year after the index ablation in patients undergoing a redo ablation for recurrent paroxysmal atrial fibrillation (PAF) despite durable pulmonary vein isolation (PVI) with either SVC isolation alone or with substrate modification including vein of Marshal ethanolisation in addition to SVC isolation alone",[27],"2026-05-07",{"date":124,"type":35},"2026-05-12",{"date":126,"type":35},"2020-09-11",{"date":128,"type":21},"2027-12-31",{"name":130,"class":108},"AZ Sint-Jan AV",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":141,"studyType":53,"phases":4,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100634098","represent-pf-registry-100634098","NCT07535268","REPRESENT-PF Registry","Prospective Multicenter Registry on the Clinical Outcomes and Safety of PFA for Atrial Fibrillation in Underrepresented Minorities (REPRESENT-PF Registry)","REPRESENT-PF","Inclusion Criteria:\n\n* All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.\n* De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.\n* Able and willing to participate in baseline and follow up evaluation over the study period\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan\n* Long standing persistent AF (AF \\> 1 year duration)\n* Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry\n* Any known contra-indication to ablation procedure at the discretion of the investigator",{"count":140,"type":21},275,"12 Months","This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.",[28,27],[27,28,30],"2026-04-09",{"date":147,"type":35},"2026-04-17",{"date":149,"type":35},"2026-03-30",{"date":151,"type":21},"2028-03-01",{"name":153,"class":108},"Vivek Reddy",2,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":165,"conditions":166,"keywords":167,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":109},"100532437","exercise-cardiac-magnetic-resonance-assessment-of-left-atrial-mechanics-following-ablation-100532437","NCT06212791","EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation","EXCLAMATORY: EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation TO Reduce Atrial Fibrillation Burden and Correlation With Exercise CapacitY Longitudinal Study","EXCLAMATORY","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of paroxysmal AF\n* Left ventricular ejection fraction ≥50%\n* Scheduled for catheter ablation\n* Able to speak, hear, and read English\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Persistent or permanent AF\n* Prior ablation (catheter based or surgical) for AF\n* Significant sinus node dysfunction\n* Implanted pacemaker or defibrillator\n* Contraindication to or inability to complete cardiovascular magnetic resonance study\n* Contraindication to or inability to complete exercise testing\n* Chronic kidney disease with estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m2\n* Severe left ventricular hypertrophy\n* Unrelated cardiomyopathy that is expected to limit exercise capacity, including but not limited to:\n\n  * Hypertrophic cardiomyopathy\n  * Cardiac amyloidosis\n  * Constrictive pericarditis\n* Pulmonary arterial hypertension\n* Prior cardiac surgery\n* Active pregnancy",{"count":164,"type":21},50,"Longitudinal, observational cohort study to evaluate changes in left atrial (LA) reservoir function during exercise and overall exertional capacity in patients following catheter ablation for paroxysmal atrial fibrillation (AF).",[27],[168,169],"Catheter ablation","Exercise capacity","2026-03-11",{"date":172,"type":35},"2026-03-12",{"date":174,"type":35},"2024-12-26",{"date":176,"type":21},"2028-03",{"name":178,"class":108},"Virginia Commonwealth University",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100601901","a-study-assessing-arrhythmia-mapping-with-a-multi-electrode-mapping-catheter-100601901","NCT07116525","A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter","Clinical Evaluation of Arrhythmia Mapping With a Paddle-shaped, High-density, Multi-electrode Mapping Catheter","FEATHER","Inclusion Criteria:\n\n* Diagnosed with and candidate for clinically indicated catheter mapping and ablation procedure for the management of ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation (participant having undergone a previous ablation procedure may be included)\n* At least one episode of the targeted arrhythmia (ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation) must have been documented by electrocardiogram (ECG), Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months prior to enrollment\n* Age 18 years or older\n* Signed Patient Informed Consent Form (ICF)\n* Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n\nExclusion Criteria:\n\n* Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non cardiac cause\n* Patients requiring left atrial procedures: left atrial size greater than (\\>) 55 millimeter (mm)\n* Left ventricular ejection fraction(LVEF) less than or equal to (\\\u003C=) 25 percentage (%) for participants with ventricular arrhythmia\n* LVEF \\\u003C= 40% for participants with atrial arrhythmia\n* Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter\n* Contraindication to anticoagulation (that is, heparin, warfarin, dabigatran)\n* History of blood clotting or bleeding abnormalities (example hypercoagulable state)\n* Myocardial infarction within the past 2 months (60 days)\n* Documented thromboembolic event (including transient ischemic attack \\[TIA\\]) within the past 12 months (365 days)\n* Uncontrolled heart failure or New York heart association (NYHA) function class IV\n* Implanted with a pacemaker or intracardiac cardiac defibrillator or appendage closure device within the past 6 weeks (42 days)\n* Patients with known untreatable allergy to contrast media\n* Active illness or active systemic infection or sepsis\n* Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study\n* Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)\n* Participants that currently have Impella or equivalent devices on the procedure date or up to 7 days prior\n* Any cardiac surgery within the past 60 days (2 months) (includes percutaneous coronary intervention \\[PCI\\])\n* Atrial septal closure within the past 6 weeks (42 days)\n* Presence of a condition that precludes vascular access\n* Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation\n* Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being\n* Concurrent enrollment in an investigational study evaluating another device or drug",{"count":188,"type":21},60,[24],"The purpose of this study is to assess the safety and feasibility of the investigational catheter for mapping the atrial and ventricular regions of the heart.",[192,28,27,193,194,195,196,197,198,199],"Scar-related Atrial Tachycardia","Ventricular Procedures","Ventricular Tachycardia","Ischemic Ventricular Tachycardia","Non-ischemic Ventricular Tachycardia","Cardiomyopathy","Idiopathic Ventricular Tachycardia","Premature Ventricular Contraction",{"date":201,"type":35},"2026-02-13",{"date":203,"type":35},"2025-09-15",{"date":205,"type":21},"2026-09-30",{"name":207,"class":42},"Biosense Webster, Inc.",6,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":217,"studyType":53,"phases":4,"briefSummary":218,"conditions":219,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":109},"100619464","determinates-of-atrial-tracking-and-prevalence-of-atrial-fibrillation-in-the-micra-av2-dance-afib-100619464","NCT07344961","Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)","DANCE AFIB","Inclusion Criteria:\n\n* Participant or legally authorized representative (LAR) provides authorization and\u002For consent per institution and geographical requirements\n* Participant has been implanted with the Micra AV2 device or is intended to receive or be treated with an eligible Micra AV2 device as per standard of care.\n* Participants with a history of paroxysmal atrial fibrillation undergoing Micra AV2 implantation, as per standard of care.\n* Age 18-85 years old with the ability to consent for the procedure\n* Participant is consented within the enrollment window of the therapy received, as applicable\n* English Speaking\n\nExclusion Criteria:\n\n* Participant who is, or is expected to be, inaccessible for follow-up\n* Participation is excluded by local law\n* Participant is currently enrolled or plans to enroll in concurrent drug\u002Fdevice study that may confound the study results\n* Participant with persistent\u002Fchronic atrial fibrillation\n* Prisoner or cognitively impaired due to the study procedures involving independent wearing of the holter monitor for research purposes.",{"count":164,"type":21},"6 Months","This is a prospective, descriptive study. Safety endpoints will not be assessed. All eligible patients that have a history of paroxysmal atrial fibrillation and an indication to undergo Micra AV2 device placement as per standard of care (SOC) across the participating sites within the Northwell Health System can be included in this analysis. Micra AV2 placement indications will be at the discretion of the treating electrophysiologist, but are expected to be predominantly atrioventricular block. Periodic device interrogations will be reviewed for the presence of effective atrial tracking during sinus rhythm . The presence of paroxysmal atrial fibrillation and the degree to which atrial activity and A4 amplitude trend changes will be assessed using a designated Medtronic Research Holter monitor that detects Micra AV2 signals at any point in the study during a episodes of sinus rhythm and atrial fibrillation. Patients who have atrial fibrillation during index hospitalization will undergo placement of the Medtronic Holter monitor as part of the standard of care index hospitalization. Eligible outpatients will undergo placement of the Medtronic Research Holter Monitor in the office.",[27],"2026-02-02",{"date":222,"type":35},"2026-02-04",{"date":224,"type":35},"2025-12-29",{"date":128,"type":21},{"name":227,"class":108},"Northwell Health",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":236,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":251},"100614615","burst-stimulation-for-paroxysmal-atrial-fibrillation-100614615","NCT07281898","Burst Stimulation for Paroxysmal Atrial Fibrillation","Efficacy of Burst Stimulation-Guided Ablation Strategy in Improving Single-Procedure Outcomes for Paroxysmal Atrial Fibrillation: A Multicenter, Prospective, Randomized Controlled Study","Burst-PAF","Inclusion Criteria:\n\n* Ages 18 to 80 years old;\n* Documented diagnosis of paroxysmal atrial fibrillation (self-terminating and lasting \\\u003C 7 days);\n* Patients scheduled for initial radiofrequency catheter ablation (RFCA) treatment;\n* Able to sign the informed consent form and comply with a minimum of 12 months of follow-up.\n\nExclusion Criteria:\n\n* Presence of organic heart disease (e.g., rheumatic heart disease, severe valvular stenosis or regurgitation, post-valve replacement, or dilated cardiomyopathy);\n* Concomitant atrial tachyarrhythmia requiring radiofrequency ablation (including typical atrial flutter and atrial tachycardia);\n* Prior history of catheter ablation for any atrial tachyarrhythmia (including atrial fibrillation, atrial flutter, or atrial tachycardia);\n* Concomitant hyperthyroidism, active malignant tumor, or other serious illness with a life expectancy of \\\u003C1 year;\n* Contraindications to anticoagulation;\n* Inability to discontinue antiarrhythmic drugs for reasons other than atrial fibrillation;\n* Pregnant or breastfeeding women.","80 Years",{"count":238,"type":21},240,[24],"Atrial fibrillation (AF) is one of the most common cardiac arrhythmias worldwide, associated with high morbidity and mortality rates. Epidemiological studies in China show that the prevalence of AF in individuals aged ≥60 years ranges from 2% to 3%, with rates continuing to rise due to population aging. Paroxysmal atrial fibrillation (PAF), if inadequately controlled, tends to progress to persistent AF, significantly increasing the risk of stroke, heart failure, and death. Catheter ablation has become a first-line therapy for drug-refractory PAF, with pulmonary vein isolation (PVI) recognized as the cornerstone procedure. However, multiple prospective studies and meta-analyses indicate that long-term recurrence rates following PVI alone remain as high as 30%-50%. This observation has prompted researchers to investigate the roles of non-pulmonary vein triggers, atrial remodeling, and electrophysiological substrate in PAF recurrence. The superior vena cava (SVC) has been identified as a common non-pulmonary vein trigger, with empirical SVC isolation demonstrating additional clinical benefits in select studies. Furthermore, the presence of atrial electrical remodeling and reentry-dependent substrate suggests that trigger-focused ablation strategies alone may be insufficient to prevent recurrence in certain PAF patients. Burst pacing-induced atrial tachyarrhythmias, such as atrial flutter or fibrillation, provide a practical method for assessing atrial substrate. Retrospective studies indicate that additional linear ablation targeting procedure-induced atrial tachycardias, such as typical atrial flutter, can significantly reduce PAF recurrence rates. However, this strategy currently lacks high-quality evidence from prospective randomized controlled trials.\n\nTo date, no large-scale randomized controlled trial (RCT) has systematically validated the impact of programmed burst pacing combined with individualized linear ablation on outcomes in PAF patients, nor have standardized induction protocols or supplementary ablation pathways been established. This study addresses a critical need for optimized treatment strategies in the field of catheter ablation, with significant clinical implications and potential for widespread application.\n\nTherefore, this prospective, multicenter, randomized controlled trial aims to systematically evaluate the efficacy and safety of this strategy in reducing post-ablation PAF recurrence, improving quality of life, and controlling AF burden. The study seeks to fill the current evidence gap and advance AF treatment from standardized protocols toward individualized precision intervention.",[27],"2025-12-10",{"date":244,"type":35},"2025-12-15",{"date":246,"type":35},"2025-10-13",{"date":248,"type":21},"2028-07-31",{"name":250,"class":108},"Zhibing Lu",3,{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":271},"100515200","ultra-hfib-redo-ultrasound-based-renal-sympathetic-denervation-vs-control-in-redo-ablation-patients-100515200","NCT05988411","ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients","Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation - Redo Ablation Procedures: A Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18;\n* Planned for a redo AF ablation procedure (paroxysmal or persistent); (prior to randomization, a technically successful AF ablation procedure, defined as successful pulmonary vein isolation, if needed, as well as bidirectional block of any attempted anatomic lesion sets such as cavotricuspid isthmus line, roofline, mitral line and superior vena cava isolation, must have been completed). Note: the clinical recurrences must primarily be atrial fibrillation, and not atrial flutter\u002Ftachycardia (that is, a prospective patient may have a AFL\u002FAT recurrences, but AF must be the dominant recurrent rhythm.)\n* History of hypertension and either:\n\n  * Documented history of SBP≥160 or DBP≥100, or;\n  * Receiving ≥1 antihypertensive medication;\n* Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements\n\nExclusion Criteria:\n\n* Long-standing persistent AF (\\>12 months); \\>3 prior atrial fibrillation ablations (lifetime); AF ablation within 3 months of enrollment; extensive scar in left atrium.\n* Individual with valvular AF or AF due to a reversible cause\n* Prior treatment with other devices for hypertension including but not limited to ROX Coupler, Mobius stent, and\u002For the CVRx barostimulator device.\n* NYHA class IV congestive heart failure;\n* Individual has renal artery anatomy that is ineligible for treatment (as determined by renal angiography);\n\n  * Main renal artery diameter \\\u003C3mm or \\>8.0 mm\n  * Main renal treatable artery length \\\u003C 20 mm (length may include proximal branches)\n  * Presence of renal artery stenosis of any origin ≥30%\n  * Calcification in renal arteries\n  * Prior renal denervation procedure\n  * Presence of abnormal kidney tumors\n  * Renal artery aneurysm\n  * Pre-existing renal stent or history of renal artery angioplasty\n  * Pre-existing aortic stent or history of aortic aneurysm\n  * Fibromuscular disease of the renal arteries\n  * Iliac\u002Ffemoral artery stenosis precluding insertion of the Paradise Catheter\n* Individual has an estimated glomerular filtration rate (eGFR) of less than 40mL\u002Fmin\u002F1.73m2, using the MDRD calculation;\n* Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to all anticoagulation)\n* Individual with known allergy to contrast medium not amendable to treatment.\n* Life expectancy \\\u003C1 year for any medical condition\n* Individual has experienced a myocardial infarction, unstable angina, cerebrovascular accident, or heart failure admission within 3 months of the baseline visit.\n* Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis.\n* Female participants who are pregnant or nursing.\n* Individual has known secondary hypertension.\n* Individual has a single functioning kidney (either congenitally or iatrogenically).\n* Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.\n* Patients concurrently enrolled in any other investigational drug or device trial that would interfere with the conduction of this protocol.",{"count":260,"type":21},250,[24],"This is a Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial. The purpose of the study is to determine the role of adjunctive renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension scheduled for a redo AF ablation procedure for paroxysmal or persistent AF. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).",[27,28],"2025-12-08",{"date":244,"type":35},{"date":267,"type":35},"2023-12-07",{"date":269,"type":21},"2027-12",{"name":153,"class":108},8,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":289,"locationsCount":5},"100541003","the-long-term-safety-and-effectiveness-evaluation-of-the-qdot-micro-system-use-in-conjunction-with-visitag-surpoint-module-for-the-treatment-of-symptomatic-drug-refractory-paroxysmal-atrial-fibrillation-100541003","NCT06324201","The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.","The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO™ System Use in Conjunction With VISITAG SURPOINT™Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation","QDOT PAS","Inclusion Criteria:\n\n1. Symptomatic drug refractory paroxysmal (AF episode terminate spontaneously within 7 days) who, in the opinion of the investigator, are candidates for ablation for AF\n2. 18 years of age or older\n3. Able and willing to participate in baseline and follow up evaluations for the full length of the sub-study\n4. Willing and able to provide informed consent for this sub-study\n\nExclusion Criteria:\n\n1. Patients who have undergone catheter ablation for atrial fibrillation (PVI, roof line, posterior wall ablation...)\n2. Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan\n3. Persistent or long-standing persistent AF\n4. In the opinion of the investigator, any known contraindication to an ablation procedure",{"count":260,"type":21},"Observational, multi-center, non-randomized, post-market study. This is a nested sub-study of the REAL AF Registry. Consecutive symptomatic drug refractory paroxysmal atrial fibrillation (PAF) patients from the registry will be screened for enrollment, prospectively or retrospectively, to this sub-study per inclusion and exclusion criteria.",[27],"2025-10-29",{"date":285,"type":35},"2025-10-31",{"date":287,"type":35},"2024-02-27",{"date":176,"type":21},{"name":290,"class":108},"Heart Rhythm Clinical and Research Solutions, LLC",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":236,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":109},"100607674","pulsed-field-ablation-of-svc-and-pv-in-paroxysmal-atrial-fibrillation-paspa-study-100607674","NCT07191626","Pulsed Field Ablation of SVC and PV in Paroxysmal Atrial Fibrillation (PASPA Study)","Pulsed Field Ablation of Superior Vena Cava in Addition to Pulmonary Vein in Paroxysmal Atrial Fibrillation: A Multicenter Randomized Controlled Trial (PASPA Study)","PASPA","Inclusion Criteria:\n\n1. Documented paroxysmal AF (episodes self-terminating within 7 days), evidenced by ECG, Holter, or event monitor\n2. Age between 18 and 80 years\n3. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Intracardiac thrombus (left atrium or left atrial appendage)\n2. Left atrial anterior-posterior diameter \\> 60 mm\n3. Absolute contraindication to anticoagulation therapy\n4. Stroke or myocardial infarction within 1 month prior to enrollment\n5. Uncontrolled hyperthyroidism\n6. Pregnancy or planning pregnancy\n7. Life expectancy less than 1 year\n8. Previous atrial fibrillation ablation procedure\n9. Known or suspected AF triggers primarily originating from the SVC (based on pre-procedure mapping, if available)\n10. Inability or unwillingness to participate in the study or comply with follow-up requirements",{"count":300,"type":21},650,[24],"The PASPA study is a multicenter, randomized trial comparing Pulmonary Vein Isolation (PVI) alone versus PVI plus Superior Vena Cava Isolation (SVCI) using Pulsed Field Ablation (PFA) in patients with paroxysmal atrial fibrillation (PAF).\n\n650 participants will be followed for 12 months. The main goal is to see if adding SVCI reduces arrhythmia recurrence without increasing complications such as phrenic nerve injury or sinus node dysfunction.",[27,304],"Paroxysmal Atrial Fibrillation (PAF)",[306,307,30,308,309],"Paroxysmal, Catheter Ablation","Catheter Ablation","Pulmonary Vein Isolation","Superior Vena Cava Isolation","2025-09-24",{"date":312,"type":35},"2025-09-25",{"date":314,"type":21},"2025-11-01",{"date":316,"type":21},"2027-11-01",{"name":318,"class":108},"Changhai Hospital",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":327,"targetDuration":329,"studyType":53,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":339},"100369264","real-world-experience-of-catheter-ablation-for-the-treatment-of-paroxysmal-and-persistent-atrial-fibrillation-100369264","NCT04088071","Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation","Real-world Experience of Catheter Ablation for the Treatment of Symptomatic ParoxysmaL and Persistent Atrial Fibrillation Using Novel CARTO Technologies: REAL AF Registry","REAL-AF","Inclusion Criteria:\n\n* Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days) who, in the opinion of the investigator, are candidates for ablation for AF\n* 18 years of age or older\n* De Novo ablation procedure unless it is a repeat for a patient whose index procedure is also in the registry\n* Able and willing to participate in baseline and follow up evaluations for the full length of the registry\n* Willing and able to provide informed consent, if applicable\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan\n* Long-standing persistent AF (AF greater than one year's duration)\n* Having a repeat ablation, unless the subject's index ablation procedure is also included in the registry\n* In the opinion of the investigator, any known contraindication to an ablation procedure",{"count":328,"type":21},15000,"1 Year","The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.",[27,28],"2025-08-06",{"date":334,"type":35},"2025-08-07",{"date":336,"type":35},"2018-01-01",{"date":128,"type":21},{"name":290,"class":108},66,{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":109},"100520210","the-impact-of-expandable-cryoballoon-on-autonomic-control-of-the-heart-100520210","NCT06053606","The Impact of Expandable Cryoballoon on Autonomic Control of the Heart","The Impact of Cryoablation Using Expandable (POLARxFIT) vs. Standard Size (POLARx) Balloon on Autonomic Control of the Heart","Inclusion Criteria:\n\n* primary PVI\n* paroxysmal atrial fibrillation\n* sinus rhythm at the admission\n* participant meets clinical criteria for PVI\n\nExclusion Criteria:\n\n* LA diameter \\\u003C38 mm or \\>50 mm\n* LVEF \\\u003C40%\n* intrinsic sinus node disease\n* advanced atrioventricular block (PR interval \\>300 ms, II or III degree AV block)\n* previous cardioneuroablation procedure\n* pregnancy\n* contraindications to anticoagulation treatment\n* any other clinical contraindications to PVI\n* known atropine intolerance","79 Years",{"count":52,"type":21},[24],"Approximately 40% of patients following cryoballoon ablation show signs of parasympathetic denervation. The presence of such effect is related to better outcomes in terms of clinical efficacy (freedom from atrial fibrillation). It could be hypothesized that larger sized balloon (POLARxFIT system) because of more antral position within the left atrium (and hence smaller distance from ganglionated plexi) might enhance this beneficial modulation of the autonomic system of the heart. This study intends to compare the effects of cryoablation employing expandable balloon (POLARxFIT) vs. standard balloon (POLARx) on autonomic system of the heart.",[27],[353,354,355,356,357,358],"atrial fibrillation","ganglionated plexus","autonomic modulation","cryoablation","cryoballoon","expandable balloon","2025-07-20",{"date":361,"type":35},"2025-07-24",{"date":363,"type":35},"2024-05-10",{"date":365,"type":21},"2026-12-31",{"name":367,"class":108},"Wroclaw Medical University",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":374,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":376,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":382,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":109},"100482726","smartwatch-and-external-holter-monitoring-to-detect-atrial-fibrillation-in-patients-with-cryptogenic-stroke-100482726","NCT05565781","Smartwatch and External Holter Monitoring to Detect Atrial Fibrillation in Patients With Cryptogenic Stroke","Impact of Non-invasive Remote Monitoring Via Wearable Technologies for Detection of Atrial Fibrillation in Patients With Cryptogenic Stroke","SMARTTHUNDER","Inclusion Criteria:\n\n* Age greater to or equal to 55 years\n* Patients with diagnosis of cryptogenic stroke after a basic study that included neuroimaging, extra\u002Fintracranial vascular evaluation, 24-hour monitoring, and echocardiogram\n* Patients with acute cortical infarction with the presence of intracranial occlusion (preferably)\n* Modified Rankin Scale (mRS) lower to 4\n\nExclusion Criteria:\n\n* Diagnosis of lacunar infarction or transient ischemic attack (TIA)\n* Diagnosis of stroke of known source: atherothrombotic due to moderate or severe symptomatic extra\u002Fintracranial stenosis, major cardioembolic cause (atrial fibrillation, anterior or apical ventricular akinesis, causal PFO, post-AMI, flutter or mitral stenosis), unusual cause (thrombophilia, arterial dissection symptomatic, toxic)\n* Use of pacemakers\n* Circumstances that may preclude the clinical follow-up or reduce the possibilities of obtaining data to achieve the objectives of the study and\u002For limit contact with the investigator (for example, transfer to a social health center)\n* Unwillingness to the use of cardiac monitoring wearable devices\n* Not understanding study procedures","55 Years",{"count":52,"type":21},[24],"Stroke recurrence largely depends on the detection of the cause and the control of vascular risk factors, with occult atrial fibrillation (AF) being one of the most important. Prolonged ambulatory cardiac monitoring is recommended for detecting occult AF. Currently, there are non-invasive monitoring devices such as the textile Holter that have proven to be useful for monitoring for up to 30 days but not longer. Another alternative is smartwatches, although they must be validated for use in the elderly population who have had a stroke.",[27,381],"Cryptogenic Stroke",[383],"Wearable Electronic Devices","2025-04-02",{"date":386,"type":35},"2025-04-04",{"date":388,"type":35},"2022-03-28",{"date":390,"type":21},"2026-09-01",{"name":392,"class":108},"Hospital Universitari Vall d'Hebron Research Institute",{"id":394,"slug":395,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":17,"minAge":401,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":409,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":109},"100557796","atrial-anomalies-predict-silent-atrial-fibrillation-detected-by-implantable-cardiac-monitor-in-cryptogenic-stroke-100557796","NCT06542770","Atrial Anomalies Predict Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Cryptogenic Stroke","Subtle Ultrasound Atrial Anomalies Predicts the Early Diagnosis of Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Patients With Cryptogenic Stroke. A Randomized Trial","CRIPTO-FAST","Inclusion Criteria:\n\n* Acute ischemic stroke or transient ischemic attack (TIA) from January 2022 to July 2023\n* Age between 50 and 89 years;\n* Undetermined origin at hospital admission according to the SSS-TOAST criteria (2):\n\n  1. Absence of major structural heart disease by cardiac ultrasound (normal global and segmental left ventricle contraction, absence of valvular\u002Frheumatic disease, absence of intracardiac shunts)\n  2. Absence of AF during 48h ECG-monitoring\n  3. Absence of major anomalies in the supra-aortic trunks ultrasound.\n\nExclusion Criteria:\n\n1. Patients with a history of hemorrhagic stroke;\n2. Presence with prior atrial fibrillation or atrial flutter;\n3. Permanent contraindication or indication for OAC for other reasons;\n4. Recent (\\\u003C1 month) major surgery or cardiac events;\n5. Presence of severe cardiac abnormalities;\n6. Patients with life expectancy \\\u003C1 year or severe stroke (modified Rankin Scale \\> 4).","50 Years","89 Years",{"count":52,"type":21},[24],"Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients. The use of implantable cardiac monitors (ICM) early after the CS has demonstrated benefits in the diagnostic yield, but the indication for ICM in the current guidelines remains unclear. Atrial contraction strain (ACS) evaluated by cardiac ultrasound could be of help to select the patients more prone to suffer from silent PAF.\n\nThe purpose of this investigation is to conduct a randomized prospective unicentric study to evaluate the usefulness of ICM for early detection of silent PAF episodes in patients with CS. Clinical and ultrasound predictors of PAF occurrence (ACS) will be studied in order to define patients needing a closer follow-up.",[27,407,408,381],"Cardiac Rhythm Disorder","Left Atrial Dilatation",[410],"Atrial strain. Implantable cardiac monitor","2024-08-02",{"date":413,"type":35},"2024-08-07",{"date":415,"type":35},"2021-01-01",{"date":417,"type":21},"2024-12",{"name":419,"class":108},"Parc de Salut Mar",{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":154},"100506314","beat-af---braking-ectopic-atrial-trends-in-atrial-fibrillation-100506314","NCT05872776","BEAT AF - Braking Ectopic Atrial Trends In Atrial Fibrillation","A Multi Center Randomized, Double Blinded, Sham Controlled, Clinical Study Aimed to Determine the Efficacy of CardiaCare™ RR2 Home-care Neuromodulation System in Reducing Atrial Fibrillation Burden and Symptoms in Paroxysmal AF Patients","Inclusion Criteria:\n\n* Men and women ages 18-85 years with history of documented paroxysmal (\\\u003C7 days) atrial fibrillation\n* AF Burden (% time in AF) of more than 0.5% and less than 25% as evident by a continuous 14 days ECG recording at baseline (at minimum 168 hours)\n* Ability and willingness to sign an informed consent form\n* Ability and willingness to use CardiaCare home care device and ECG chest patch and has an available smart phone\n* Known symptomatic AF event over the recent 3 months\n* Willing not to change the antiarrhythmic treatment\n\nExclusion Criteria:\n\n* Hemodynamic instability (systolic blood pressure \\\u003C100mmHg or heart rate\\>170 bpm at Baseline) during recruitment visit\n* Known history or current diagnosis of atrial flutter\n* An active myocardial infarction evident from ECG\n* Recent stroke or myocardial infarction (\\\u003C6 months)\n* History of sick sinus syndrome 2nd or 3rd degree AV block, bifascicular block or prolonged (PR\\>300ms) 1st degree AV block\n* Unilateral or bilateral vagotomy\n* History of persistent AF with documented AF episodes of \\>7 days\n* Significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant valvular diseases or valvular AF)\n* History of Impaired systolic function with EF\\\u003C40 % or NY Class III or IV heart failure classification\n* Dilatated left atria with a diameter \\> 50mm as evident by an echocardiogram\n* Currently enrolled in another study\n* Recurrent vaso-vagal syncopal episodes\n* Pregnancy or breast feeding\n* Pacemaker or CRTD or any implanted electrical stimulating device\n* History of epilepsy or seizures\n* Peripheral neuropathy or dermatological condition affecting the tested upper extremity area\n* Unsuitable for participating in the study according to attending physician","85 Years",{"count":164,"type":21},[24],"Paroxysmal AF subjects with a documented ECG event of AF will be recruited to the study To assess the efficacy of CardiaCare™ RR2 wearable home-care neuromodulation system in reducing AF burden and symptoms in Paroxysmal AF patients",[27],"2024-06-18",{"date":434,"type":35},"2024-06-20",{"date":436,"type":35},"2023-02-16",{"date":438,"type":21},"2025-03",{"name":440,"class":42},"Ziv HealthCare Ltd.",{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":17,"minAge":447,"maxAge":236,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":450,"briefSummary":451,"conditions":452,"keywords":453,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":109},"100355771","computed-tomogram-myocardial-thickness-map-guided-pulmonary-vein-isolation-vs-empirical-pulmonary-vein-isolation-in-cryoballoon-ablation-for-paroxysmal-atrial-fibrillation-utmost-af-ii-100355771","NCT03912324","Computed Tomogram Myocardial Thickness Map Guided pulmOnary Vein iSolaTion vs. Empirical Pulmonary Vein Isolation in Cryoballoon Ablation for Paroxysmal Atrial Fibrillation (UTMOST AF II)","Inclusion Criteria:\n\n1. Patient with paroxysmal atrial fibrillation who is scheduled for ablation procedure and ≥20 and ≤80 years of age\n2. Left atrium size \\\u003C 50mm\n3. paroxysmal atrial fibrillation that is recurrence during antiarrhythmic drug treatment or is not able to use an antiarrhythmic drug.\n4. Patient who is indicated for anticoagulation therapy (for prevention of cerebral infarction)\n\nExclusion Criteria:\n\n1. Patients with persistent or permanent atrial fibrillation\n2. Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected\n3. Patients with severe renal impairment or CT imaging difficulty using contrast media\n4. Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery\n5. Patients with active internal bleeding\n6. Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs\n7. Patients with valvular atrial fibrillation (mitral stenosis \\>grade 2, mechanical valve, mitral valvuloplasty)\n8. Patients with a severe comorbid disease\n9. Expected survival \\\u003C 1 year\n10. Drug addicts or alcoholics\n11. Patients who cannot read the consent form (illiterates, foreigners, etc.)\n12. Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study","20 Years",{"count":449,"type":21},220,[24],"New parameters or methods, such as ablation index, have been developed for the quantification of high-frequency energy used in pulmonary vein isolation, but there is no known method for atrial fibrillation considering individual differences in atrial tissue. The atrium is only 1\u002F3 of the thickness of the ventricle and is thinner in women and older than men or young people.\n\nThe aim of this study was to evaluate the efficacy and safety of radiofrequency energy therapy using atrial individual differences. In order to reflect the thickness of the atrium, we will use the unipolar and bipolar maps and the myocardial thickness map using computed tomography (CT) images. To evaluate the efficacy and safety of energy titration therapy by random assignment of high frequency energy therapy group, CT image application high frequency energy therapy group, and existing empirical high frequency therapy group.",[27],[454,455],"Atrial fibrillation","Pulmonary vein isolation","2024-06-10",{"date":458,"type":35},"2024-06-13",{"date":460,"type":35},"2021-10-06",{"date":462,"type":21},"2025-04",{"name":464,"class":108},"Yonsei University",{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":472,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":4},"100529070","phase-4-role-of-eplerenone-in-reducing-recurrence-of-atrial-fibrillation-in-patient-with-structural-heart-disease-100529070","NCT06168994","Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease","Inclusion Criteria:\n\n\\- paroxysmal AF who reverted to sinus rhythm either medically or electrically without appropriate secondary cause of primary AF\n\n•AF attack should be documented with ECG\n\nExclusion Criteria:\n\n* 1-patients are currently on eplerenone or spironolactone 2-hyperkalemia 3-impaired renal function(if CrCl \\\u003C50ml\u002Fmin or serum creatinine\\>2 mg\u002Fdl) 4-patient on beta blocker and calcium channel blocker (non- dihydropyridine) 5-prosthetic valve 6-severe mitral stenosis 7-thyroid dysfunction 8-WPW 9-severe liver disease 10-persistent or permanent AF 11-pregnancy or breast feeding 12-LV EF\\\u003C50% 13-known hypersensitivity or drug reaction to amiodarone 14-acute coronary syndrome 15-refusal of consent",{"count":52,"type":21},[473],"PHASE4","The aim of this study is to study synergistic effect of eplerenone as Selective aldosterone receptor antagonist with amiodarone compared with amiodarone only in reducing recurrence of atrial fibrillation in patient with structural heart disease",[27],"2023-12-05",{"date":478,"type":35},"2023-12-13",{"date":480,"type":21},"2024-02-01",{"date":482,"type":21},"2027-05-20",{"name":484,"class":108},"Assiut University",{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":17,"minAge":93,"maxAge":236,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":109},"100251965","clinical-usefulness-of-virtual-ablation-guided-catheter-ablation-of-atrial-fibrillation-virtual-rotor-mapping-and-catheter-ablation-100251965","NCT02558699","Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation","CUVIA-AF II","Inclusion Criteria:\n\n* AF patient age 19\\~80\n* Diagnosis of AF patients who performed catheter ablation of atrial fibrillation due to uncontrolled pulse rate by anti-arrhythmic drug therapy.\n\nExclusion Criteria:\n\n* AF patients who have severe heart deformations or vascular disease.\n* The patient who have renal disease of eGFR\\\u003C30mL\u002Fmin\n* The patients who had been performed catheter ablation of atrial ablation and MAZE.\n* The patients who missed out to recording of 3D CT, echo and electrocardiography.\n* the patient have experienced major hemorrhagic complication\n* The patient have experienced ischemic cerebral infarction more 2 times\n* The patient who have risk of ischemic cerebral infarction (CHA2DS2-VASc Score \\>5)",{"count":493,"type":21},110,[24],"Radiofrequency catheter ablation is effective in the treatment of patients with paroxysmal atrial fibrillation. In order to reduce the recurrence rate after catheter ablation, the investigators propose to apply 'virtual' ablation on patient-specific atria by simulating 3D atrial computer model. The investigators will conduct virtual rotor mapping in the patient specific atrial model. Then, the investigators will compare the clinical outcome of conventional circumferential pulmonary vein isolation and additional rotor ablation guided by virtual rotor mapping.",[27],"2022-12-28",{"date":499,"type":35},"2023-01-03",{"date":501,"type":35},"2018-08-24",{"date":128,"type":21},{"name":464,"class":108}]